Table 2.

Change at weeks 6 and 12 in menopause-related symptoms and general impairment.

Measure	Week	M (SD)	n	M (SD)	n	Change from Baseline		% Improvement		p	d (95% CI)
		Structured Attention Control		Clinical Hypnosis		Structured Attention Control	Clinical Hypnosis	Structured Attention Control	Clinical Hypnosis
HF FREQUENCY	Baseline	75.21 (3.11)	94	75.26 (2.82)	93
	6 week	68.26 (3.10)	90	27.19 (2.48)	84	−6.95	−48.07	9.24	63.87	p<.001	1.25 (38.84–47.85)
	12 week	62.32 (3.43)	87	19.44 (1.96)	78	−12.89	−55.82	17.13	74.16	p<.001	1.27 (36.15–49.67)
HF-SCORE	Baseline	22.94 (1.23)	94	23.43 (1.02)	93
	6 week	21.03 (1.15)	90	6.71 (.79)	84	−1.91	−16.72	8.32	71.36	p<.001	1.23 (12.22–16.86)
	12 week	19.41 (1.36)	87	4.61 (.56)	78	−3.53	−18.83	15.38	80.32	p<.001	1.21 (12.60–17.54)
HF MONITOR	Baseline	8.85 (.75)	88	10.41 (1.00)	84
	6 week	9.48 (.87)	78	6.15 (.81)	68	0.63a	−4.26	7.11‡	40.92	p<.001	.52 (2.30–5.91)
	12 week	7.97 (.70)	70	4.49 (.59)	49	−0.88	−5.92	9.94	56.86	p<.001	.67 (2.00–5.46)
HFRDIS	Baseline	5.75 (.24)	94	5.87 (.23)	93
	6 week	4.71 (.27)	90	1.85 (.21)	84	−1.04	−4.02	18.08	69.02	p<.001	1.10 (2.37–3.47)
	12 week	4.43 (.28)	87	1.05 (.20)	78	−1.32	−4.82	22.96	82.11	p<.001	1.22 (2.74–4.02)
SLEEP (PSQI)	Baseline	11.89 (.48)	94	11.69 (.56)	93
	6 week	10.85 (.51)	90	6.10 (.47)	84	−1.04	−5.59	8.75	43.49	p<.001	1.04 (3.65–5.84)
	12 week	10.66 (.55)	87	5.42 (.47)	78	−1.23	−6.27	10.34	53.63	p<.001	1.07 (3.69–5.93)

Abbreviations: HF, Hot Flash; HF-SCORE, Composite Score of Hot FlashFrequency X Hot Flash Severity; HF MONITOR, expert-rated hot flashes via skin conductance recording; HFRDIS, Hot Flash Related Daily Interference Scale, Mean score; HADS, Hospital Anxiety and Depression Scale -Anxiety subtotal; CESD, Center for Epidemiologic Studies -Depression Total Score; PSQI, Pittsburgh Sleep Quality Index -Global score; CI, 95% confidence interval. Effect size measures are Cohen’s d not adjusted for baseline and 95% confidence intervals for mean differences.

^aIndicates increased hot flashes